Alrise announces acquisition of its ImSus® drug delivery technology by Ferring International Center S.A.
14.12.2020 / The drug delivery specialist Alrise Biosystems GmbH has entered into an Asset Purchase and Exclusive License Agreement with Ferring International Center S.A. for the development and commercialisation of products manufactured with Alrise’s ImSus® platform technology.
Alrise and Ferring have been working together since 2017 on the development of an injectable, controlled-release formulation of a peptide therapeutic. Based on the successful partnership Ferring has now exercised its option to enter into a definite agreement to further leverage and get exclusive access to Alrise’s process knowhow and intellectual property rights. The parties have committed not to disclose the contractual terms and conditions as well as details of the on-going product development.
“We are pleased that we were able to continue and strengthen our successful collaboration with Ferring”, stated Dr. Heiko Seemann, Alrise’s Managing Director. “This agreement paves the way to making the first product utilising our ImSus® technology platform available to patients.”
“On this occasion we would like to express our special thanks to our investors IBB Ventures and Creathor Venture for their long-standing trust and support”, Dr. Volker Rindler, Alrise’s Managing Director, added. “Our thanks also go to our consultants from tytonis b.v. and Bay Pharma GmbH for their help in various business development matters.”
Alrise Biosystems GmbH is a drug delivery company located in the Biotech Park Berlin-Buch and is managed by Dr. Heiko Seemann und Dr. Volker Rindler. Through application of its ImSus® technology platform Alrise develops drug-loaded micro particle formulations, which are used for injectable, controlled-release depot products. The company has been financed primarily through venture capital investments from the VC companies Creathor Venture and IBB Ventures
Quelle: Press release of Alrise Biosystems GmbH